Mrs Eifiona Wood

• MSc: Health Economics and Management
  University of Sheffield, 2005
• BSc: Bachelor of Pharmacy
  University of Wales Institute of Science and Technology, Cardiff, 1992

Eifiona is a Senior Research Fellow in Pharmacoeconomics at the Centre for Health Economics and Medicine Evaluation at Bangor University. She holds a Bachelors degree in Pharmacy from the University of Wales Institute of Science and Technology, Cardiff (1992) and in 2005 completed a Masters degree in Health Economics and Management at the University of Sheffield. 

After graduating from Cardiff, Eifiona spent 8 years as a hospital pharmacist specialising in oncology, provision of clinical services, funding and business support in both the UK and Australia. Following on from this, Eifiona pursued a career in health economics within the pharmaceutical industry and the consulting environment, working on a wide range of projects including developing and adapting health economic models, budget impact models, cost of illness studies, HTA submissions, orphan drugs and environmental analyses.

She is experienced in a variety of therapy areas including oncology, neurology, respiratory, fertility and mental health. Eifiona also has widespread experience in the development of value communications, manuscripts and posters, and has co-authored peer-reviewed papers in health economics. 

Eifiona joined CHEME in 2015 and is currently working on a range of pharmacoeconomic projects, including the NERVES trial on treatments for sciatica, the CF Start study in cystic fibrosis and the CASTLE study for children with rolandic epilepsy. She also undertakes peer-review of All Wales Medicines Strategy Group submissions and provides health economic support to the All Wales Therapeutics and Toxicology Centre.

2023

• PublishedChanging Agendas on Sleep, Treatment and Learning in Epilepsy (CASTLE) Sleep-E: A protocol for a randomised controlled trial comparing an online behavioural sleep intervention with standard care in children with Rolandic epilepsy
  Al-Najjar, N., Bray, L., Carter, B., Collingwood, A., Cook, G., Crudgington, H., Dietz, K., Hardy, W., Hiscock, H., Hughes, D., Morris, C., Rouncefield-Swales , A., Saron, H., Spowart, C., Stibbs-Easton, L., Tudur Smith, C., Watson, V., Whittle, L., Wiggs, L., Wood, E., Gringas, P. & Pal, D. K., 10 Mar 2023, In: BMJ Open. 13, 3, e065769.
  Research output: Contribution to journal › Article › peer-review
• PublishedCosts of orphan medicinal products: longitudinal analysis of expenditure in Wales
  Pijeira Perez, Y., Wood, E. & Hughes, D., 1 Nov 2023, In: Orphanet Journal of Rare Diseases. 18, 1, 342.
  Research output: Contribution to journal › Article › peer-review
• PublishedThe impact of parent treatment preference and other factors on recruitment: lessons learned from a paediatric epilepsy randomised controlled trial
  Carter, B., Bray, L., Al-Najjar, N., Tort Piella, A., Smith, C. T., Spowart, C., Collingwood, A., Crudgington, H., Currier, J., Hughes, D., Wood, E., Martin, R., Morris, C., Roberts, D., Rouncefield-Swales , A., Sutherland, H., Watson, V., Cook, G., Wiggs, L., Gringas, P. & Pal, D., 6 Feb 2023, In: Trials. 24, 1, 83.
  Research output: Contribution to journal › Article › peer-review

2021

• PublishedMicrodiscectomy compared with transforaminal epidural steroid injection for persistent radicular pain caused by prolapsed intervertebral disc: the NERVES RCT
  Wilby, M. J., Best, A., Wood, E., Burnside, G., Bedson, E., Short, H., Wheatley, D., Hill-McManus, D., Sharma, M., Clark, S., Bostock, J., Hay, S., Baranidharan, G., Price, C., Mannion, R., Hutchinson, P. J., Hughes, D., Marson, A. & Williamson, P. R., Apr 2021, In: Health Technology Assessment. 25, 24, 86 p.
  Research output: Contribution to journal › Article › peer-review
• PublishedSurgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica secondary to herniated lumbar disc (NERVES): a phase 3, multicentre, open-label, randomised controlled trial and economic evaluation
  Wilby, M. J., Best, A., Wood, E., Burnside, G., Bedson, E., Short, H., Wheatley, D., Hill-McManus, D., Sharma, M., Clark, S., Baranidharan, G., Price, C., Mannion, R., Hutchinson , P. J., Hughes, D., Marson, A. G. & Williamson, P., 1 May 2021, In: The Lancet Rheumatology. 3, 5, p. e347-e356
  Research output: Contribution to journal › Article › peer-review

2020

• PublishedThe new and non-transparent Cancer Drugs Fund
  Wood, E. & Hughes, D., Jan 2020, In: PharmacoEconomics. 38, 1, p. 1-4
  Research output: Contribution to journal › Article › peer-review

2019

• PublishedAdalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT
  Ramanan, A. V., Dick, A. D., Jones, A. P., Hughes, D., McKay, A., Rosala_Hanna, A., Williamson, P. R., Hardwick, B., Hickey, H., Rainford, N., Kolamunnage-Dona, R., Culeddu, G., Plumpton, C., Wood, E., Compeyrot-Lacassagne, S., Woo, P., Eldesten, C. & Beresford, M. W., 10 Apr 2019, In: Health Technology Assessment. 23, 15, p. 1-174 174 p.
  Research output: Contribution to journal › Article › peer-review
• PublishedCost-effectiveness analysis of adalimumab for the treatment of uveitis associated with Juvenile Idiopathic Arthritis
  Hughes, D. A., Culeddu, G., Plumpton, C. O., Wood, E., Dick, A. D., Jones, A. P., McKay, A., Williamson, P. R., Compeyrot Lacassagne, S., Hardwick, B., Hickey, H., Woo, P., Beresford, M. W. & Ramanan, A. V., Mar 2019, In: Ophthalmology. 126, 3, p. 415-424
  Research output: Contribution to journal › Article › peer-review
• PublishedCost-effectiveness analysis of adalimumab for the treatment of uveitis associated with Juvenile Idiopathic Arthritis: Authors’ reply.
  Hughes, D., Culeddu, G., Plumpton, C., Wood, E., Dick, A. D., Beresford, M. W. & Ramanan, A. V., Mar 2019, In: Ophthalmology. 126, 3, p. e24-e25
  Research output: Contribution to journal › Letter › peer-review

2018

• PublishedLessons learnt from a discontinued randomised controlled trial: Adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC)
  Williams, N., Jenkins, A., Goulden, N., Hoare, Z., Hughes, D., Wood, E., Foster, N. E., Walsh, D. A., Carnes, D., Sparkes, V., Hay, E. M., Isaacs, J., Konstantinou, K., Morrissey, D., Karppinen, J., Genevay, S. & Wilkinson, C., 31 Jul 2018, In: Trials. 19, 408.
  Research output: Contribution to journal › Article › peer-review

2017

• PublishedSubcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC): a randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica
  Williams, N. H., Jenkins, A., Goulden, N., Hoare, Z., Hughes, D. A., Wood, E., Foster, N. E., Walsh, D. A., Carnes, D., Sparkes, V., Hay, E. M., Isaacs, J., Konstantinou, K., Morrissey, D., Karppinen, J., Genevay, S. & Wilkinson, C., 31 Oct 2017, In: Health Technology Assessment. 21, 60, p. 1-180 180 p.
  Research output: Contribution to journal › Article › peer-review

2016

• PublishedConducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches
  Hughes, D., Charles, J. M., Dawoud, D. M., Edwards, R. T., Holmes, E. A., Jones, C. L., Parham, P., Plumpton, C., Ridyard, C. O., Lloyd-Williams, H., Wood, E. M. & Yeo, S., May 2016, In: Pharmacoeconomics. 34, 5, p. 447-461
  Research output: Contribution to journal › Article › peer-review

2015

• PublishedNICE recommendations: why no disinvestment recommendations to offset investment decisions?
  Hughes, D., Tuersley, L. V., Hughes, D. A., Wood, E. M. & Tuersley, L., 19 May 2015, In: BMJ. 350
  Research output: Contribution to journal › Article › peer-review

2011

• PublishedA cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK
  Lowin, J., Bergman, A., Chaudhuri, K. R., Findley, L. J., Roeder, C., Schifflers, M., Wood, E. & Morris, S., 6 Jul 2011, In: Journal of Medical Economics. 14, 5, p. 584-93 10 p.
  Research output: Contribution to journal › Article › peer-review
• PublishedThe economic burden of advanced Parkinson’s disease: an analysis of a UK patient dataset
  Findley, L. J., Wood, E., Lowin, J., Roeder, C., Bergman, A. & Schifflers, M., 17 Jan 2011, In: Journal of Medical Economics. 14, 1, p. 130-9 10 p.
  Research output: Contribution to journal › Article › peer-review

2010

• PublishedCost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population
  Asukai, Y., Valladares, A., Camps, C., Wood, E., Taipale, K., Arellano, J., Cassinello, A., Sacristán, J. A. & Dilla, T., 29 Jan 2010, In: BMC Cancer. 10, p. 26
  Research output: Contribution to journal › Article › peer-review

2004

• PublishedAxillary staging for operable primary breast cancer
  Hind, D., Wyld, L., Wood, E., Beverley, C. & Reed, M. W., 19 Jul 2004, In: Cochrane Database of Systematic Reviews. 2004, 3, CD004561.
  Research output: Contribution to journal › Article › peer-review

2020

• CASTLE (Changing agendas on sleep, treatment & learning in epilepsy)

  The CASTLE study is focused on rolandic epilepsy, which is the most common type of childhood epilepsy and affects about one-sixth of all children with epilepsy in the UK.

  Throughout the CASTLE study, we’ll be working with children, parents, doctors and nurses to choose the best ways to measure health and quality of life for children with epilepsy. The research will also include talking to parents and children about their experiences in relation to sleep, taking medication, learning and how taking part in the study has impacted on them.

  9 Mar 2020 – 5 Dec 2023

  Links:

  • http://castlestudy.org.uk/
  Activity: Other (Contributor)

2019

• Pharmaceoeconomics Short Course, Bangor University

  13 Sep 2019

  Activity: Participation in Academic workshop, seminar, course (Speaker)
• Health Services Research Summer School

  11 Jul 2019

  Activity: Participation in Academic workshop, seminar, course (Speaker)
• AWTTC 2019-20 health economics support in relation to the assessment of new medicines

  2019 – 2020

  Activity: Other (Contributor)

2018

• CF-START (Cystic Fibrosis [CF] anti-staphylococcal antibiotic prophylaxis trial)

  The aim of the CF START trial is determine the safest and most effective way to treat infants diagnosed with Cystic Fibrosis (CF) with antibiotics. At the moment infants in the UK are prescribed an antibiotic, usually flucloxacillin, every day to prevent infection with a bacteria (bug) called Staphylococcus aureus (SA).

  Although this approach appears to help prevent SA infection, there is a worry that it may make earlier infection with other bugs, such as Pseudomonas aeruginosa (PsA) more likely.

  This trial is designed to test if infants with CF are more likely to get an earlier infection from PsA if they are taking flucloxacillin on a daily basis (“Prevent and Treat”) or Antibiotics in a more targeted manner (“Detect and Treat”).

  1 Sep 2018

  Links:

  • http://www.cfstart.org.uk/
  Activity: Other (Contributor)
• Developing a repurposed medicine for Duchenne muscular dystrophy

  1 Aug 2018

  Activity: Other (Contributor)
• Health Services Research Summer School, Bangor University

  6 Jul 2018

  Activity: Participation in Academic workshop, seminar, course (Speaker)
• Pharmaceoeconomics Short Course, Bangor University

  13 Apr 2018

  Activity: Participation in Academic workshop, seminar, course (Speaker)
• AWTTC 2018-19 health economics support in relation to the assessment of new medicines

  2018 – 2019

  Activity: Other (Contributor)

2017

• AWTTC 2017-18 health economics support in relation to the assessment of new medicines

  2017 – 2018

  Activity: Other (Contributor)

2016

• SYCAMORE (effectiveness of adalumimab in the treatment of juvenile paediatric uveitis)

  1 Sep 2016 – 1 Sep 2018

  Activity: Other (Contributor)
• AWTTC 2016-17 health economics support in relation to the assessment of new medicines

  2016 – 2107

  Activity: Other (Contributor)

2015

• NERVES (effectiveness of trans-foraminal epidural steroid injections)

  1 Mar 2015 – 30 Sep 2019

  Links:

  • http://www.nervestrial.org.uk/
  Activity: Other (Contributor)

2013

• New Medicines Group (External organisation)

  Deputy Health Economist, New Medicines Group

  2013 – 2016

  Activity: Membership of committee (Member)